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Abstract
Background: The DNA repair protein O6-Methylguanine-DNA methyltransferase (MGMT) confers resistance to
alkylating agents. Several methods have been applied to its analysis, with methylation-specific polymerase chain
reaction (MSP) the most commonly used for promoter methylation study, while immunohistochemistry (IHC) has
become the most frequently used for the detection of MGMT protein expression. Agreement on the best and
most reliable technique for evaluating MGMT status remains unsettled. The aim of this study was to perform a
systematic review and meta-analysis of the correlation between IHC and MSP.
Methods: A computer-aided search of MEDLINE (1950-October 2009), EBSCO (1966-October 2009) and EMBASE
(1974-October 2009) was performed for relevant publications. Studies meeting inclusion criteria were those
comparing MGMT protein expression by IHC with MGMT promoter methylation by MSP in the same cohort of
patients. Methodological quality was assessed by using the QUADAS and STARD instruments. Previously published
guidelines were followed for meta-analysis performance.
Results: Of 254 studies identified as eligible for full-text review, 52 (20.5%) met the inclusion criteria. The review
showed that results of MGMT protein expression by IHC are not in close agreement with those obtained with MSP.
Moreover, type of tumour (primary brain tumour vs others) was an independent covariate of accuracy estimates in
the meta-regression analysis beyond the cut-off value.
Conclusions: Protein expression assessed by IHC alone fails to reflect the promoter methylation status of MGMT.
Thus, in attempts at clinical diagnosis the two methods seem to select different groups of patients and should not
be used interchangeably.
Background
The cellular protein O6-Methylguanine-DNA methyl-
transferase (MGMT) is a DNA-repair protein that
removes mutagenic and cytotoxic adducts from O6-gua-
nine in DNA. Alkylating agents are among the most
widely used chemotherapeutic drugs in human cancer.
Alkylation induced by these compounds can produce
either lethal double-strand cross-links, as is the case
with bifunctional nitrosoureas (BCNU), or induce mis-
match abortive repair and DNA fragmentation, as is the
case with temozolomide [1-4]. The toxicity of alkylating
agents is reduced in the presence of MGMT. Thus,
MGMT confers resistance to alkylating agents in a wide
spectrum of human tumours by reversing DNA toxicity.
In brain neoplasms, hypermethylation of CpG islands in
the MGMT gene promoter region, rather than mutation
or deletion, is the major mechanism for the loss of
MGMT function [2,5-7]. As a consequence, tumours
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with epigenetic silencing of MGMT gene become more
sensitive to the killing effects of alkylating agents. More-
over, several studies have demonstrated that epigenetic
silencing of MGMT is a relevant prognostic factor in
patients with glioblastoma, anaplastic glioma and low
grade glioma [8-14]. In fact, MGMT status has recently
been recommended as a stratifying factor for patients in
glioma trials [15,16].
Many methods and protocols have been applied for
MGMT analysis in gliomas, but to date there is no con-
sensus on which strategy should be primarily employed
[17]. Methylation-specific polymerase chain reaction
(MSP) is the most commonly used test [9]. Indeed, in
glioblastoma clinical trials, a strong correlation of the
methylation status of MGMT with temozolomide
response and patient outcome was shown. However,
there are some methodological problems that limit the
usefulness of this method in a routine diagnostic setting:
it is complex, time-consuming, and highly dependent on
tissue quality [18,19]. MGMT status can also be assessed
by analyzing protein expression by immunohistochemis-
try (IHC). IHC is a reliable, commonly used method in
diagnostic histopathology that is available in most
laboratories. In addition, IHC is easier to use, less
expensive and faster than MSP [20-29], and conse-
quently it has become the most frequently used method
for the detection of MGMT protein expression in the
past decade [30]. In this line, some retrospective clinical
reports have also shown a prognostic association
between MGMT protein expression and/or activity and
outcome.
However, studies aimed at evaluating the correlation
between aberrant promoter methylation and loss of pro-
tein expression have yielded contradictory results, not
only in brain tumours but also in other neoplasms.
While we and other authors have shown that the rela-
tionship between MGMT promoter methylation status
and MGMT protein expression is not absolute [31],
other studies have found a strong correlation between
homogeneous immunoreactivity and unmethylated pro-
moter [32]. At present, there is a lack of data on which
to base recommendations for a specific method or pro-
tocol for MGMT testing. Accordingly, there is a strong
need for systematic comparisons and validation of intra-
and interlaboratory reproducibility of different methods
for MGMT assessment in order to identify the best
method for clinical MGMT testing [33].
The aim of this study was to perform a systematic
review and a meta-analysis of the correlation between
MGMT IHC and MSP in a large array of human brain
and non-brain systemic tumours. Our primary objective
was to assess the diagnostic accuracy of IHC at different
cut-off values for test positivity. Because test accuracy is
not a fixed property of a test [34], we have also studied
several possible sources of heterogeneity such as sub-
groups of patients, differing interpretations of results,
and study design features.
Methods
This systematic review and meta-analysis was performed
following previously published guidelines [34-37].
Literature Search
A computer-aided search of MEDLINE (1950-October
2009), EBSCO (1966-October 2009) and EMBASE (1974-
October 2009) was performed for relevant publications.
Medical Subject Heading (MeSH) terms with accompany-
ing entry terms were used (Additional file 1). To identify
additional published, unpublished and ongoing studies, we
entered relevant studies identified from the above sources
into PubMed and then used the Related Articles function.
The Science Citation Index was searched to identify arti-
cles citing relevant publications. The reference lists of all
selected papers were also reviewed for search completion.
Only English-language literature was considered eligible.
Titles and abstracts were screened by two reviewers (M.B.
and J.I.) to identify relevant articles. Discrepancies were
resolved by consensus.
Criteria for inclusion of studies
Studies meeting inclusion criteria were those comparing
MGMT protein expression by IHC with MGMT promo-
ter methylation by MSP as the reference test in the
same cohort of patients. Not only brain tumour series
but also others involving any type of cancer were con-
sidered eligible whenever both diagnostic tests were
used in the same population. Studies on cellular lines
were excluded. Information had to be available to allow
the construction of the diagnostic two-by-two table with
its four cells: true positive, false negative, false positive
and true negative.
Index test and reference test
IHC performed with different commercially available
antibodies was the test under evaluation and MSP was
considered the reference test, as it is the most com-
monly used.
Quality assessment and data extraction
Methodological quality of included studies was assessed
independently by two observers (M.B. and J.I.) using the
QUADAS tool [38] which was specifically developed for
systematic reviews of diagnostic test accuracy studies.
The tool is based on 14 items scored as “yes”, “no”, or
“unclear”. The items from the QUADAS tool and their
interpretation can be found in Additional file 2.
Data extraction was performed independently by two
authors (M.B. and J.I.), and included author and date,
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journal of publication, time of data collection, testing
procedure, study population, reference test, performance
of the reference test and of the index test, cut-off value
used for immunolabeling, QUADAS-items, whether
histological analysis of the tissue used for DNA extrac-
tion was performed or not, the percentage of methylated
cases by MSP, the effect of methylated promoter/protein
expression on survival, and data for two-by-two table.
A quality score was not used as a weighting variable
because of its subjectivity [39]. The STARD [40] check-
list and flow diagram were also followed as
recommended.
Data analysis
Studies reporting insufficient data for the construction
of a two-by-two table were excluded from final analyses.
Data from the two-by-two tables were used to calculate
sensitivity, specificity and diagnostic odds ratio for each
study. We present individual study results graphically by
plotting the estimates of sensitivity and specificity (and
their 95%CI) in both forest plots and the receiver oper-
ating characteristic (ROC) space. Heterogeneity was
investigated in the first instance through visual inspec-
tion of the relationship between pairs of accuracy esti-
mates in forest plots and sROC space [41]. As one of
the primary causes of heterogeneity in test accuracy stu-
dies is the threshold effect, which arises when different
cut-offs are used in different studies to define a positive
(or negative) test result, the computation of the Spear-
man correlation coefficient between the logit of sensitiv-
ity and logit of 1-specificity was also performed. A
strong positive correlation suggests this threshold effect.
In order to explore for heterogeneity other than thresh-
old effect, the chi-square and Cochrane-Q tests were
used. A low p-value suggests the presence of heteroge-
neity beyond what could be expected by chance alone.
The inconsistency index (I-squared) was used to quan-
tify the amount of consistency–that is, the percentage of
total variation across studies due to heterogeneity rather
than chance. Statistical heterogeneity can be defined as
low, moderate and high for I2 values of 25%, 50% and
75% [42]. When a substantial heterogeneity was found,
the reasons for it were explored by relating study level
covariates to diagnostic odds ratio, using meta-regres-
sion techniques. Subgroup analyses trying to identify
homogeneity were then performed but in all cases pool-
ing was done using methods based on a random effect
model. This model assumes that in addition to the pre-
sence of random error, differences between studies can
also result from real differences between study popula-
tions and procedures, and it includes both within-study
and between-study variations. Sensitivity and specificity
were compared between these subgroups using the z-
test [36]. Publication bias was examined by construction
of a funnel-plot. The x-axis consisted of the natural
logarithm of the diagnostic odds radio, and the y-axis
was the standard error, which is considered the best
choice [43]. In the absence of bias the graph resembles
a symmetrical inverted funnel because the accuracy esti-
mates from smaller studies scatter more widely at the
bottom of the graph, with the spread narrowing with
increasing accuracy among larger studies. If there is
publication bias the funnel plot will appear skewed and
asymmetrical. Although useful, interpretation of the
funnel-plot is subjective; for this reason the Egger’s
regression test became necessary in order to measure
the funnel-plot asymmetry numerically [44]. The inter-
cept provides a measure of the assymetry: the greater its
deviation from zero the more pronounced the
asymmetry.
Statistical analysis was performed using Meta-Disc
software http://www.hrc.es/investigacion/metadisc_en.
htm[45]. The analysis for publication bias was per-
formed using CMA-1 http://www.Meta-Analysis.com.
Two-sided P < .05 was considered to be statistically
significant.
Results
Results of the search and study characteristics
The initial search strategy yielded 812 articles, 254 of
which were eligible for full-text review. Of these, 182
studies were ruled out, and 72 were selected for data
extraction. All selected studies were diagnostic cohort
studies. Seventeen studies [20,26,30,46-59] reported data
that were insufficient for the construction of the two-
by-two table, and in 3 studies [60-62] protein expression
was assessed by a test other than IHC. These 20 studies
were not included in the analysis. Thus, 52 relevant stu-
dies constitute the basis of this analysis (17 glioma stu-
dies, 3 non-glioma brain tumour studies and 32 non-
brain systemic tumour studies) comprising a total of
2,943 patients: 539 with primary brain tumours, 178
with brain metastases of various solid tumours and
2,226 with non-brain systemic cancer (Figure 1). Addi-
tional file 3 and Additional file 4 show the characteris-
tics of included studies.
Regarding the IHC analysis, the most commonly used
antibody was anti-MGMT mouse monoclonal clone
MT3.1 (from Dako, Chemicon International, NeoMar-
kers, Santa Cruz Biotechnology or Kamiya Biomedical
Laboratories), which was reported in 39 out of 52 (75%)
studies, followed by anti-MGMT mouse monoclonal
antibody clone MT23.2 (from Zymed Laboratory) which
was used in 4 (7.6%) series. Other commercially avail-
able anti-MGMT antibodies were reported in 7 (13.4%)
additional studies. In one study, no laboratory specifica-
tion was reported [63]. MGMT immunoexpression was
qualitatively analyzed in 16 out of 52 (30.8%) studies.
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Accordingly, a semiquantitative score which estimates
the fraction of positive cells was used in 36 studies
(69.2%). Indeed, MGMT expression was evaluated by
semiquantitative scoring in the majority of the brain
tumour studies (18 out of 20) and in 18 out of 32 sys-
temic tumour series. As shown in Additional file 3 and
Additional file 4, different cut-off values were used, ran-
ging from 5% to 80%. Statistically significant association
between IHC and MSP was found in 9 out of 20 brain
tumour studies, while in the group of non-brain sys-
temic tumours this concordance between the two tests
was observed in 29 of the 32 series (90.6%).
Regarding the MSP analysis, genomic DNA was iso-
lated from formalin-fixed paraffin-embedded tissue in
26 studies (50%), whereas in 21 cases it was isolated
from fresh-frozen samples (40.3%). In five studies (9.6%)
DNA was isolated from both types of specimens.
Sodium bisulfite modification of isolated DNA was per-
formed using commercially available DNA methylation
kits in nearly half of them (24 out of 52) including DNA
Methylation Kit (Zymo Research), Methylamp DNA
Modification Kit (Epigentek Inc), CpGenome DNA
Modification Kit (Intergen), and Fast DNA Modification
Kit (Chemicon).
Methodological quality of included studies
Figure 2 and Additional file 5 show assessment of meth-
odological quality of included studies using the QUA-
DAS tool. Inclusion of a representative patient spectrum
and explanation of selection criteria or withdrawals did
not constitute a limitation of any study. Eight studies
reported the use of some modification of the original
MSP as the reference test [32,64-70]. In approximately
one quarter of the studies, partial verification bias was
not clearly avoided as not all cases evaluated with the
index test were verified using the reference test. Some
authors reported that only tumour samples with an esti-
mated tumour cell content of at least 80% were used for
molecular studies [71], while in others this requirement
was not clearly reported.
Immunohistochemical expression was scored semi-
quantitatively or qualitatively in all but six studies
[1,64,69,72-74], in which interpretation of the index test
was not satisfactorily explained by the authors. We did
not expect any differential verification bias because all
studies used the same reference test for the whole
cohort of patients. In 84.6% of the studies, the authors
did not unequivocally state whether assessment of the
reference test was blinded for the IHC results, and in
73% of the series, no details were reported about blind-
ing of the index test. Seventeen studies reported no
details about any uninterpretable or indeterminate index
test results [2,64,66,70,73-85].
Data analysis
Tabular results for sensitivity, specificity, likelihood
ratios and diagnostic odds ratios for all studies are given
in Additional file 6. At this early stage of the analysis,
the pooled summary of accuracy measures was not
taken into account, as significant heterogeneity was sug-
gested when observing the forest plots and the sROC
space (Figures 3A and 3B). No statistically significant
difference was observed when exploring for threshold
effect, either considering all studies (n = 52, Spearman
correlation coefficient = -0.022; p = 0.881) or just the
subgroup of studies in which semiquantitative scoring
was used (n = 36, Spearman correlation coefficient =
0.037; p = 0.833). However, statistical heterogeneity was
observed for sensitivity (chi-square = 234.28; df = 42 (p
< 0.0001), inconsistency (I2) = 79.5%), specificity (chi-
Figure 2 Methodological quality graph.
Figure 1 Flow diagram of inclusion process.
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square = 300.84; df = 48 (p < 0.0001), I2 = 84%), positive
LR (Cochrane-Q = 265.33; df = 48 (p < 0.0001), I2 =
81.9%), negative LR (Cochrane- Q = 201.46; df = 48 (p
< 0.0001), I2 = 76.2%), and diagnostic odds ratio
(Cochrane-Q = 143.88; df = 48 (p < 0.0001), I2 =
66.6%), thus suggesting other sources of heterogeneity
across the studies. Accordingly, meta-regression analysis
with the following covariates was performed: 1) type of
tissue used for MSP, as paraffin embedded specimens
may not yield enough quality DNA to successfully per-
form the test [86]; 2) anti-MGMT antibody used, as the
best agreement between MSP and IHC results seems to
be achieved when using the MT23.2 antibody [33]; and
3) type of tumour analyzed. Results suggest that the
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type of tumour is strongly associated with accuracy
(RDOR 5.36; 95% CI[2.42-11.86], p < 0.01) (Additional
file 7).
In the next step, a second meta-regression analysis was
performed for the subgroup of 36 studies in which semi-
quantitative scoring for IHC was used, and the cut-off
value was also included as covariate. Interestingly, the
type of tumour (primary brain tumour vs. others) was
also selected as an independent covariate of accuracy
estimates beyond cut-off value, type of tissue or type of
antibody used. MGMT protein expression by IHC for
brain tumours is associated with a more than four-fold
lower accuracy compared to other tumours (RDOR 4.38;
95% CI[1.82-10.54], p = 0.0017) (Additional file 8).
The final step of the analysis was pooling accuracy
estimates in homogeneous subgroups of studies with
identical type of tumour and identical cut-off value. To
rule out an implicit threshold effect due to naturally
occurring variations in the interpretation between obser-
vers, laboratories or devices, the Spearman rank correla-
tion was performed, and no evidence of threshold effect
within these groups was found. Overall, the summary
estimates found ranged from 0.53; 95% CI[0.33-0.73] to
0.79; 95% CI[0.73-0.84] for sensitivity and from 0.60;
95%CI[0.52-0.67] to 0.93; 95%CI[0.91-0.95] for specifi-
city (Additional file 9).
To further evaluate diagnostic accuracy for MGMT
protein expression by IHC when identical scoring and
cut-off values were used, we determined the Q*index.
Figures 4A and 4B show that the Q*index was 0.64 and
the area under the curve (AUC) 0.68 for brain tumour
studies, while the Q*index was 0.80 and the AUC 0.87
for non-brain tumour series, indicating a statistically sig-
nificant higher level of overall accuracy in systemic
tumours (z-statistic 4.354, p < 0.0001). This difference
remained statistically significant when we included all
studies in the analysis (z-statistic 5.722, p < 0.0001).
Finally, the Egger’s regression test for the detection of
publication bias showed an asymmetrical distribution of
the points in the funnel-plot (Intercept 1.55; 95%CI
[0.61-2.49], p = 0.002) (Figure 5), indicating a potential
publication bias.
Discussion
The relevance of MGMT status as a potential prognostic
or predictive factor in malignant glioma patients is sup-
ported by a number of independent studies. At present,
detection of MGMT promoter methylation by MSP is
the most commonly used method and for this reason it
is considered the reference test in the present review.
However, concerning day-to-day clinical practice, MSP
is not yet part of the routine diagnostic work-up while
MGMT assessment at RNA or protein-level are used
[22,33]. The exact incidence of promoter methylation,
protein or RNA expression varies according to the
assessment test and among different studies [87]. An
optimal method for diagnostic purposes should be
widely available, easy to establish, cost-effective, repro-
ducible both within a given laboratory and among differ-
ent laboratories, and capable of yielding results that
show consistent association with patient outcome
[19,33]. In this regard MSP is a highly sensitive qualita-
tive technique, but IHC has several advantages over it
[88].
Although strong agreement between MSP and IHC
has been previously reported, there is growing evidence
that MGMT promoter methylation assessment through
MSP does not correlate well with MGMT protein
expression as detected by IHC in brain tumours
[25,26,31,68,89]. In addition, some studies have shown
that MGMT promoter methylation and MGMT protein
expression cannot be used interchangeably to predict
patient survival or glioma chemosensitivity [68,90].
Results from the present meta-analysis support this evi-
dence and suggest that cases selected by IHC may not
always correspond to those selected by MSP. In fact,
diagnostic accuracy estimates for MGMT protein
expression by IHC were significantly lower for brain
tumours than for other non-brain tumours (sensitivity,
53-64% vs. 60-81% respectively; specificity, 60-84% vs.
80-93% respectively). Similarly, positive and negative
likelihood ratios did not provide convincing diagnostic
accuracy for IHC in brain tumours (Additional file 9).
Accordingly, the type of tumour (primary brain vs. non-
brain systemic tumour) turned out to be an independent
covariate of accuracy estimates in the meta-regression
analysis beyond other methodological covariates such as
cut-off value and type of antibody.
The reasons for these findings are not clear and differ-
ent putative causes must be taken into consideration.
First, there is a lack of a consistently defined cut-off
value for the semiquantitative immunohistochemical
scoring. Capper et al. proposed a cut-off of 15% immu-
nolabeled cells for GBM and 35% for low grade gliomas
[22], Nakasu et al. proposed a cut-off value of 10-20%
[88], and Preusser et al. found the best agreement
between MSP and IHC results when using a cut-off of
50% [20]. It is important to note that the cut-off value
was not an independent covariate of accuracy in the
present meta-regression analysis, whereas the type of
tumour (primary brain vs non-brain) was independently
associated with greater accuracy (Additional files 7 and
8). In addition, interobserver variability in discriminating
positive and negative cells, specific immunostaining and
background is another technical aspect of the IHC pro-
cedure [20]. Even when studies use the same explicit
threshold, their implicit threshold may differ, especially
if interpretation of the test requires pathology
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judgement [35]. Importantly, histological analysis of the
tissue used for DNA extraction is not always performed
(Additional file 3 and Additional file 4), and when the
area of tumour used for MSP analysis is different from
the one studied with IHC, necrosis and/or an overlarge
sample of normal tissue might hamper the MSP results.
Third, due to the fact that MSP relies on the different
susceptibility of methylated versus unmethylated cyto-
sines to sodium bisulfite modification and subsequent
selective primers amplification, it is highly dependent on
tissue quality and quantity, primer design, bisulfite treat-
ment adequacy and PCR conditions [19]. Finally, MSP is
so highly sensitive that a methylation band may be
obtained even if cells that carry MGMT promoter
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methylation represent a small proportion among the
majority of cells with unmethylated promoter [1]. Con-
versely, IHC may not be able to detect small clusters of
cells that have lost protein expression [91].
Apart from these technical issues, there are other con-
founding factors that may lead to false positive methyla-
tion results. Although it has been stated that the
presence of a methylated MGMT allele can only be
attributed to neoplastic cells [8,10,92], some authors
have demonstrated that MGMT promoter methylation
may occur in non-neoplastic central nervous system tis-
sue [3] or in normal-appearing mucosa several centi-
metres away from digestive tumours [56,93]. Moreover,
Candiloro et al. [94] have shown low levels of methyla-
tion in peripheral blood of healthy individuals with the
T allele of the rs16906252 polymorphism.
Moreover, regulation of MGMT expression in brain
tumours seems to be a complex phenomenon in which
abnormal methylation of the promoter region may not
be the only determining factor [1,47,95-97]. Similar to
genetic and chromosomal events, epigenetic changes
may also be tissue- and tumour-specific [98,99]. In fact,
the inconsistency between promoter methylation and
protein expression assessed by IHC in gliomas is not
limited to the MGMT gene, but has also been observed
for other genes such as PTEN [100]. Gliomas are het-
erogeneous tumours and intratumoural heterogeneity of
MGMT staining and methylation is a well-known event.
Over time, variations in the methylation status of
MGMT promoter within the same tumour have also
been described, although the relevance of these events is
unclear [31,89,101]. Interestingly, some factors, such as
glucocorticoids, ionizing radiation and chemotherapy,
can induce MGMT expression [26,102]. Thus, a further
question to be addressed is whether tumour recurrences
exhibit the MGMT status as the pre-treatment tumour
or a different one. Unfortunately, data on this topic are
limited and contradictory [103]. While some studies
have demonstrated an increase in MGMT immunostain-
ing [84] or a lower frequency of MGMT promoter
methylation [87,104,105] in recurrent gliomas after che-
motherapy, other authors have not observed any change
[84,103,106]. Finally, both an increase and a decrease in
MGMT expression have also been described for recur-
rent tumours [22,76,87,107-109]. A higher protein
expression might indicate that the MGMT gene has
been up-regulated by the treatment, although other pos-
sible explanations, such as selection of chemoresistant
cells with high MGMT protein levels or intratumoral
regional variations, can not be excluded [26,84,109].
Finally, methylation is not biallelic in some tumours,
leaving one allele actively expressing the protein while
MGMT promoter methylation may be also observed [110].
In fact, MGMT gene is located on chromosome 10q, a
region lost in the vast majority of GBM, implying that even
in those GBM without promoter methylation, MGMT hap-
loinsufficiency is likely [101]. Moreover, MGMT promoter
CpG islands may present a differential pattern of methyla-
tion along the region, with some CpGs being more impor-
tant than others with regard to gene transcription. In this
sense, it has been suggested that the region commonly
investigated by MSP might not to be among those that
best correlate with protein expression [90].
In an attempt to avoid some of the above mentioned
problems, quantitative or semiquantitative methods such
as MethylLight® quantitative MPS, pyrosequencing,
COBRA, etc. [66,67,70,83,87,89,111] have been reported
by different groups in recent years. Whether these meth-
ods are more appropriate than MSP remains to be
demonstrated in large cohorts of patients. Quantitative
methods seem to provide better discrimination than clas-
sical gel-based MSP. However, as Karayan-Tapon et al.
[46] note, before these methods can be used as clinical
biomarkers, validation of them is required. Whichever
gene is used for normalization, no quantitative-MSP
assay can give a real, absolute measurement, and this
might be a restriction. Moreover, completely quantitative
or semiquantitative assays that normalize to a control
gene or the copy number of the unmethylated MGMT
promoter sequence might underestimate MGMT methy-
lation, because contaminating nontumoral tissue will
contribute to the signal of the normalizing gene [112].
Both MGMT status at protein level and promoter
methylation have been correlated with prognosis and
chemosensitivity in glioma patients. As is shown in
Additional file 3 and Additional file 4, the prognostic and
predictive value of protein expression has been evaluated
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Figure 5 Funnel-plot for the assessment of potential
publication bias.
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in some studies with contradictory results. Several authors
have reported a significant association of MGMT expres-
sion assessed by immunohistochemistry with patients’
overall or progression-free survival [22,23,31,88,113-117].
Some of them have even shown MGMT protein expres-
sion to be an independent predictor in the multivariate
analysis [31,84,85,115,116,118,119], whilst others have
demonstrated a lack of correlation [29,46,58,74]. However,
most published data were obtained from heterogeneous
groups of patients with different grades and histologies, as
well as distinct treatment protocols [31]. Although differ-
ences in study design could explain, at least in part, these
contradictory results, other possibilities should be consid-
ered. In this sense, while those neoplastic cells that do not
express MGMT may not be able to correct DNA damage
induced by chemotherapy, loss of MGMT expression can
also be a negative prognostic factor because of an
increased susceptibility to acquiring other mutations
[120-122]. Furthermore, due to variable interobserver
agreement, insufficient correlation with MGMT promoter
methylation status and the lack of a firm association with
patient outcome [20,29,103], MGMT IHC has not proved
to be a clinically usable biomarker for routine diagnostic
purposes and clinical decision-making.
Our review has several limitations. First, we excluded
17 studies because they did not provide data allowing
construction of two-by-two tables, potentially resulting
in less precise estimates of pooled diagnostic accuracy.
Second, the statistical power of this meta-analysis was
limited by the relatively small sample size of most
included studies. Third, the QUADAS tool revealed that
in approximately two-thirds of the studies partial verifi-
cation bias was not clearly avoided, as not all cases eval-
uated with the index test went on to receive verification
using the reference test. Another important aspect of
study quality is the blinding of results of experimental
and reference tests [123]. Unfortunately, in 84% of the
studies, assessment of the reference test blinded for the
IHC results was not explicitly stated by the authors, and
in 73% of them no details were reported about blinding
of the index test. Finally, publication bias was found in
the present meta-analysis. Exclusion of non-English-lan-
guage studies could contribute to explaining this fact,
although a preference for publishing studies reporting
positive results is a more plausible explanation [44].
Conclusions
The present systematic review and meta-analysis has
shown that assessment of MGMT protein expression by
IHC is not in good concordance with results obtained
with the MSP test. Discordance between the two tests
seems to be higher for brain tumours even when compar-
ing subgroups with identical cut-off value. Therefore, it
seems that MGMT promoter methylation does not
always reflect gene expression and, accordingly, the two
methods cannot be used interchangeably. We conclude
that protein expression assessed by IHC alone fails to
reflect the promoter methylation status of MGMT, and
thus in clinical diagnostic attempts the two methods will
not select the same group of patients. This fact can be of
crucial importance when stratifying patients in clinical
studies according to their MGMT status.
Despite all the above mentioned aspects, MSP cur-
rently remains the most established method and the
best approach to assessing MGMT status. It is also the
technique for which the most convincing clinical corre-
lations have been reported and, thus, it should be con-
sidered the reference test. Unfortunately, it is a relatively
complex and time-consuming method not apt for rou-
tine clinical implementation in many centres [19].
However, the analytical and clinical performance of
MGMT immunoassaying seems to be inappropriate for
routine diagnostic purposes. This fact, along with the
lack of a robust association with MGMT promoter
methylation as demonstrated in the present meta-analy-
sis, precludes its use as a valuable biomarker for clinical
decision making. It remains to be determined whether
novel anti-MGMT antibodies directed against other epi-
topes would improve its performance [20].
Accordingly, some authors have suggested the feasibility
of using MSP combined with IHC for prognostic and pre-
dictive purposes [104,116]. Immunohistochemistry may
represent a useful preliminary test to identify methylated
cases while MSP should be performed in non-immunor-
eactive cases to identify truly methylated tumours [70].
Again, this issue deserves further investigation.
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